Ipamorelin

Also known as: Ipamorelin acetate, NNC 26-0161

Strong Evidence

Classification

Peptide

Regulatory Status

unknown

Overview

Ipamorelin is a synthetic pentapeptide ghrelin mimetic that stimulates growth hormone release from the anterior pituitary; it was first identified in 1998.

Evidence and limitations

Human/preclinical evidence breakdown is not available in this record.

Expansion-batch evidence packet requires human review before publication. | FDA Category 2 peptide listings were revised in April 2026; current ipamorelin status must be confirmed against the live FDA page at review time. | CAS/UNII/ChEMBL identifiers not yet resolved from structured databases. | Compiled draft requires human review before publication.

Pathways

Ipamorelin is a synthetic pentapeptide ghrelin mimetic that stimulates growth hormone release from the anterior pituitary; it was first identified in 1998.

Sources

https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks (opens in a new tab)
https://www.fda.gov/media/182088/download (opens in a new tab)
https://link.springer.com/article/10.1007/s00384-014-2030-8 (opens in a new tab)

Educational reference only — not medical advice.